17,261 trials
Gastrointestinal Cancer Metastatic · Renal Cell Cancer Metastatic · Non Small Cell Lung Cancer Metastatic
Primary: Progression Free Survival
Adult Alveolar Soft Part Sarcoma · Adult Angiosarcoma · Adult Desmoplastic Small Round Cell Tumor
Primary: Maximum-tolerated Dose of Gamma-secretase Inhibitor RO4929097, Defined as the Dose Level Where no More Than 1 Out of 6 Patients Experience DLT at the Highest Dose Level…
Trichotillomania
Primary: Mean Change in Massachusetts General Hospital Hairpulling Scale Baseline to Post-treatment — 6.695 Units on a scale — p=<0.05
Nonalcoholic Steatohepatitis · Non-alcoholic Fatty Liver Disease
Primary: Change in Alanine Aminotransferase (ALT) — -37.8; -14.9 U/L — p=0.0195
AIDS-Related Kaposi Sarcoma · Recurrent Kaposi Sarcoma
Primary: Maximum Tolerated Dose of Lenalidomide Defined as the Dose Level at Which 0/6 or 1/6 Subjects Experience Dose Limiting Toxicity (DLT) With the Next Higher Dose Having at…
Breast Cancer
Primary: The Proportion of Subjects That Complete an Intervention of Lovaza™ 4 Grams Per Day — 0.94 proportion of enrolled participants
Migraine · Headache
Primary: Mean Change From Baseline in Monthly Migraine Days — 8.2; 8.2; -1.7; -1.3 Days/month — p=0.33153
Amyotrophic Lateral Sclerosis · ALS
Primary: The Difference in the Changes of Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R) Between Treatment Groups and Control Groups. — -1.36; -4.67…
Hirschsprung Disease
Primary: Number of Patients Diagnosed With Hirschsprung-associated Enterocolitis (HAEC). — 10; 7 participants — p==0.897
Plantar Warts
Primary: Lesion Assessment — 8.42; 9.14; 8.42; 8.71 millimeters — p=<0.001
Huntington Disease
Primary: Safety and Tolerability of PBT2 in Patients With HD — 32; 30; 28 participants
Diabetes Mellitus, Type 1
Primary: Percentage of Participants With Hemoglobin A1c (HbA1c) Reduction Greater Than or Equal to (>=) 0.4 Percent (%) and no Increase in Body Weight — 14.5; 36.9; 41.4; 85.5…
Breast Cancer
Primary: Objective Response Rate (as Determined by Investigator): the Percentage of Patients Assigned to a Treatment Arm With a Confirmed Best Response of CR or PR. — 0; 1; 1; 0…
Hepatitis D, Chronic
Primary: Number of Participants With Alanine Aminotransferase (ALT) Normalization Plus Negative Hepatitis D Virus (HDV) Ribonucleic Acid (RNA) at 48 Weeks After End of Treatment…
Rheumatoid Arthritis
Primary: American College of Rheumatology 20 (ACR20) Response at 3 Months — 27; 56 Participants